Biolevate Raises €30 Million Series A & Opens Boston Office to Meet Surging Demand

Biolevate, reinventing life sciences operations for the AI era, led by Joel Belafa and the team, announced a €30 million Series A funding round co-led by RAISE France – the investment vehicle of French entrepreneur Aymar Hénin, and Orange Ventures, with participation from MSD Global Health Innovation Fund (MGHIF), Station F, and existing investor EQT Ventures.

Biolevate has raised new funding to scale its AI platform for regulated life sciences and expand into the US with a new Boston office.

Founded in Paris by former Dataiku engineers and AI researchers, the company develops an agentic platform that turns scientific and regulatory knowledge into evidence-backed, auditable workflows. The platform now supports research, clinical trials, regulatory intelligence, drug discovery, and development, with capacity to run 100,000 agents concurrently.

Biolevate reports 16× faster literature reviews, an 80% efficiency gain in regulatory intelligence and compliance, and 20× ARR growth over the past year. The company now has more than a dozen enterprise customers, including Sanofi, and has grown to 50 employees.

The funding will support international expansion, product development, and continued growth across the life sciences market.

Joël Belafa, Co-Founder and CEO at Biolevate, said:

“We started Biolevate with a mission-driven team united by the belief that AI could improve millions of lives if we empowered the right people and solved the right technological challenges. Today, our vision is becoming reality. Customers are increasingly embracing AI automation at scale, grounded in evidence and under rigorous human oversight. This milestone, paired with the extraordinary traction we are experiencing, confirms that we are on track to build a global champion in this emerging category and, more importantly, to deliver on AI’s promise for healthcare.”

Aymar Hénin, Entrepreneur and newly appointed Chairman of Biolevate, said:

“Biolevate is addressing one of the most important challenges in life sciences: turning the extraordinary potential of AI into trusted, evidence-grade automation that can operate at scale in regulated environments. The company’s rapid commercial progress, deep technological expertise and ambitious team give us strong conviction in its ability to become a global category leader. I am proud to support that journey as an investor and to work closely with Joël and the team as Chairman.”

Jérôme Berger, Head of Group Strategy & Venture Capital at Orange, added:

“In healthcare, the value of AI depends on the trust people can place in the knowledge it produces. Biolevate’s approach to making complex scientific information accessible, reliable, and usable, strongly aligns with our vision of responsible AI, and we are delighted to co-lead this new stage of the company’s growth.”

𝐑𝐞𝐦𝐨𝐭𝐞 𝐇𝐢𝐫𝐞 𝐨𝐫 𝐁𝐮𝐢𝐥𝐝 𝐖𝐢𝐭𝐡 𝐔𝐬: 𝐁𝐮𝐢𝐥𝐝𝐰𝐞𝐫𝐤𝐬 helps technology companies build in India: two ways. Hire vetted remote engineers, product leaders, designers, and GTM professionals directly onto your team. Or partner with a proven development studio to design, build, and ship your product end-to-end. Learn More At: menlotimes.com/buildwerks